About Neos Therapeutics (NASDAQ:NEOS)
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300
Debt
Debt-to-Equity Ratio7.47%
Current Ratio2.20%
Quick Ratio1.84%
Price-To-Earnings
Trailing P/E Ratio-3.06
Forward P/E Ratio-5.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.02 million
Price / Sales9.50
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book30.37
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-264.80%
Return on Equity-437.92%
Return on Assets-60.52%
Miscellaneous
Employees138
Outstanding Shares29,000,000
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics (NASDAQ:NEOS) announced its quarterly earnings data on Thursday, March, 15th. The company reported ($0.49) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.61) by $0.12. The firm earned $7.79 million during the quarter, compared to analyst estimates of $9.30 million. Neos Therapeutics had a negative net margin of 264.80% and a negative return on equity of 437.92%. View Neos Therapeutics' Earnings History.
What price target have analysts set for NEOS?
5 brokers have issued 1 year price targets for Neos Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' stock price to reach $15.25 in the next year. View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Neos held its Analyst Day on March 22-23, which included a dinner with management and Behavioral Medicine KOLs Dr. Brian Barash and Dr. Birgit Amann, a presentation, and a manufacturing facility tour." (3/23/2018)
- 2. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (3/22/2018)
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include MediciNova (MNOV), Innate Pharma (IPHYF), ProMetic Life Sciences (PFSCF), Isotechnika Pharma (AUPH), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Mersana Therapeutics (MRSN), Cytokinetics (CYTK), Corium International (CORI), GTX (GTXI) and Clearside Biomedical (CLSD).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Dr. Vipin K. Garg Ph.D., Chief Exec. Officer, Pres and Director (Age 60)
- Mr. Richard I. Eisenstadt M.B.A., Chief Financial Officer (Age 60)
- Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
- Mr. Russ McMahen, VP of R&D
- Dr. Carolyn R. Sikes Ph.D., VP of Clinical Affairs
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
Has Neos Therapeutics been receiving favorable news coverage?
News articles about NEOS stock have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of 0.07 on Accern's scale. They also assigned media coverage about the company an impact score of 46.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $8.20.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $237.77 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neos Therapeutics (NASDAQ:NEOS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Neos Therapeutics in the last 12 months. Their average twelve-month price target is $15.25, suggesting that the stock has a possible upside of 85.98%. The high price target for NEOS is $20.00 and the low price target for NEOS is $12.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.83 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.25 | $16.20 | $14.8333 | $14.8333 |
| Price Target Upside: | 85.98% upside | 83.05% upside | 43.32% upside | 83.13% upside |
Neos Therapeutics (NASDAQ:NEOS) Consensus Price Target History
Neos Therapeutics (NASDAQ:NEOS) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Neos Therapeutics (NASDAQ:NEOS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Neos Therapeutics (NASDAQ NEOS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 49.33%
Neos Therapeutics (NASDAQ NEOS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/31/2016 | Bryant Fong | Director | Buy | 1,500 | $6.54 | $9,810.00 | 1,500 |  |
| 8/25/2016 | Richard I Eisenstadt | CFO | Buy | 3,710 | $6.82 | $25,302.20 | 3,710 | |
| 6/13/2016 | Juergen Martens | Insider | Buy | 10,000 | $9.90 | $99,000.00 | 10,000 | |
| 5/19/2016 | Alan L Heller | Director | Buy | 10,000 | $7.61 | $76,100.00 | 379,888 | |
| 5/19/2016 | Thomas P Mcdonnell | Insider | Buy | 3,000 | $7.56 | $22,680.00 | 3,000 | |
| 5/18/2016 | Gregory J Robitaille | Director | Buy | 7,442 | $7.55 | $56,187.10 | 55,677 | |
| 4/20/2016 | Presidio Partners 2007, L.P. | Major Shareholder | Sell | 20,367 | $9.98 | $203,262.66 | 1,575,419 | |
| 4/15/2016 | Presidio Partners 2007, L.P. | Major Shareholder | Sell | 57,968 | $10.23 | $593,012.64 | 1,623,997 | |
(Data available from 1/1/2013 forward)
Neos Therapeutics (NASDAQ NEOS) News Headlines
| Source: |
|
Neos Therapeutics (NASDAQ:NEOS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neos Therapeutics (NASDAQ:NEOS) Income Statement, Balance Sheet and Cash Flow Statement
Neos Therapeutics (NASDAQ NEOS) Stock Chart for Saturday, April, 21, 2018
Loading chart…
